Efficacy of Aprepitant (Emend®) in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 1, 2012

Primary Completion Date

June 29, 2017

Study Completion Date

June 29, 2017

Conditions
NauseaVomitingChildhood Cancer
Interventions
DRUG

Ondansetron, dexamethasone, aprepitant

Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.

DRUG

Ondansetron, Dexamethasone, placebo

Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.

Trial Locations (1)

73104

Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT01661335 - Efficacy of Aprepitant (Emend®) in Children | Biotech Hunter | Biotech Hunter